
Coya Therapeutics, Inc. (NASDAQ:COYA – Free Report) – HC Wainwright lowered their FY2026 earnings per share estimates for Coya Therapeutics in a research note issued on Thursday, November 12th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($1.50) per share for the year, down from their previous estimate of ($1.30). HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.53) per share. HC Wainwright also issued estimates for Coya Therapeutics’ Q4 2026 earnings at ($0.45) EPS and Q4 2027 earnings at ($0.34) EPS.
Coya Therapeutics (NASDAQ:COYA – Get Free Report) last posted its earnings results on Tuesday, November 10th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.11). Coya Therapeutics had a negative return on equity of 71.48% and a negative net margin of 643.44%. The business had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.11 million.
COYA has been the subject of a number of other reports. Wall Street Zen cut Coya Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a report on Thursday, October 15th. BTIG Research reaffirmed a “buy” rating and issued a $16.00 target price on shares of Coya Therapeutics in a research report on Tuesday, September 15th. Chardan Capital reaffirmed a “buy” rating and set a $14.00 target price on shares of Coya Therapeutics in a research note on Wednesday, August 12th. Finally, Roth Capital reaffirmed a “buy” rating and set a $12.00 target price on shares of Coya Therapeutics in a research note on Monday, August 24th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $15.00.
Read Our Latest Stock Report on Coya Therapeutics
Coya Therapeutics Stock Down 4.2%
Shares of Coya Therapeutics stock opened at $3.00 on Monday. Coya Therapeutics has a 52 week low of $2.72 and a 52 week high of $6.62. The business’s fifty day simple moving average is $4.26 and its 200-day simple moving average is $4.57. The firm has a market cap of $70.38 million, a PE ratio of -2.16 and a beta of 0.70.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in COYA. Goldman Sachs Group Inc. boosted its position in shares of Coya Therapeutics by 77.3% during the third quarter. Goldman Sachs Group Inc. now owns 46,421 shares of the company’s stock worth $233,000 after buying an additional 20,241 shares during the period. Marshall Wace LLP grew its stake in Coya Therapeutics by 29.6% during the 3rd quarter. Marshall Wace LLP now owns 323,849 shares of the company’s stock worth $1,622,000 after purchasing an additional 74,056 shares in the last quarter. Allworth Financial LP increased its stake in shares of Coya Therapeutics by 1,200.0% during the second quarter. Allworth Financial LP now owns 13,000 shares of the company’s stock worth $76,000 after buying an additional 12,000 shares during the period. AXQ Capital LP purchased a new stake in shares of Coya Therapeutics in the 2nd quarter valued at approximately $116,000. Finally, Long Corridor Asset Management Ltd acquired a new position in shares of Coya Therapeutics during the second quarter worth $227,000. 39.75% of the stock is currently owned by institutional investors and hedge funds.
Coya Therapeutics Company Profile
Coya Therapeutics is a clinical-stage biotechnology company developing therapies that aim to enhance the function of regulatory T cells, immune cells that help control inflammation. Its research focuses on potential treatments for neurodegenerative and other diseases associated with inflammation and immune dysfunction. The company’s development programs include biologic and cell-based approaches, with candidates under investigation for conditions including amyotrophic lateral sclerosis (ALS). These therapies remain in development; Coya does not have an approved commercial product.
Recommended Stories
- Five stocks we like better than Coya Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
